Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy

C. Gridelli, A. Contegiacomo, R. Lauria, M. Gentile, G. Airoma, S. De Placido, F. Perrone, G. Ferrante, A. R. Bianco

Research output: Contribution to journalArticlepeer-review

Abstract

CCNU and methotrexate were employed as salvage treatment in 34 small cell lung cancer patients resistant to CAV/PE alternating induction chemotherapy. In the 33 evaluable patients we observed an objective response rate of 21.2% and 3% complete response; median survival was 4 months with 2 patients alive 18 months from starting salvage chemotherapy. The treatment was well tolerated. CCNU and methotrexate has shown to be a moderately active and tolerable salvage treatment for small cell lung cancer after CAV/PE alternating first-line chemotherapy.

Original languageEnglish
Pages (from-to)506-510
Number of pages5
JournalTumori
Volume77
Issue number6
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy'. Together they form a unique fingerprint.

Cite this